Streetbeat News

Revenues

CHH

Choice Hotels Intl (NYSE:CHH) received mixed analyst ratings in the latest quarter, with 4 indifferent and 1 somewhat bearish. The average 12-month price target is $127.4, down from $131.67, with a high estimate of $143.00 and a low of $96.00. Analysts adjusted their ratings and price targets, reflecting market conditions and company performance. Choice Hotels operates 628,000 rooms across 13 brands and closed on its Radisson acquisition in August 2022. The company's revenue growth rate is 2.73%, with a net margin of 21.51%, ROE of 144.05%, ROA of 4.18%, and a high debt-to-equity ratio of 20.79.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 2:00 pm

NVDA

Nvidia's AI processors are expected to remain a significant growth driver for the PC and server markets in 2024, as indicated by sources from component and peripheral suppliers.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:48 pm

CRBJY

LGFRY

MCHI

Chinese stocks, particularly in the real estate sector, experienced a sharp decline following weak property market data. The iShares MSCI China ETF (MCHI) dropped 1.8% in pre-market trading. Longfor Group Holdings ADR (LGFRY) and China Resources Land ADR (CRBJY) are expected to be impacted, with their performance data delayed. The property market data showed a 26% year-on-year drop in average daily home sales, and the manufacturing PMI indicated economic contraction. The Chinese yuan also fell by 0.6% against the dollar.

Portfolio Pulse from Neil Dennis

January 02, 2024 | 1:44 pm

CDIO

Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) has been assigned a dedicated CPT PLA code by the AMA for its AI-driven CHD detection test, PrecisionCHD. This code is crucial for securing reimbursement and broadening access to the test. PrecisionCHD, which uses genetic-epigenetic analysis and AI, aims to improve CHD diagnosis and patient outcomes while reducing healthcare costs. The test's scalability and remote deployment capabilities can enhance care delivery, especially in underserved areas. The innovation of PrecisionCHD has been recognized in a study and by Vizient, Inc.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:42 pm

CHRS

Coherus BioSciences, Inc. (NASDAQ: CHRS) has launched LOQTORZI, the first and only FDA-approved treatment for nasopharyngeal carcinoma (NPC) in all lines of therapy. LOQTORZI is now available through select specialty distributors and is indicated for use in combination with chemotherapy for first-line treatment and as monotherapy for patients with disease progression after platinum-containing chemotherapy. The launch follows positive results from the JUPITER-02 and POLARIS-02 studies, which showed significant improvements in progression-free survival and overall survival. Coherus aims to make LOQTORZI the new standard of care for NPC and is committed to supporting patients with programs to reduce out-of-pocket costs.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:31 pm

BABA

PDD

Alibaba Group Holding Limited (BABA) is facing significant challenges, including a loss of direction, regulatory issues, and declining staff morale. The company was overtaken in market capitalization by PDD Holdings Inc (PDD) and its shares are now 75% off their peak. Alibaba's new CEO, Eddie Yongming Wu, is tasked with consolidating control over its diverse businesses. The company's restructuring efforts and competition from ByteDance's Douyin and PDD's Pinduoduo and Temu add to its struggles. Alibaba's growth strategy is unclear, with mixed signals from dividends and share buybacks, and uncertainty around its fintech affiliate Ant and logistics arm Cainiao's IPO. BABA shares traded lower by 2.01% at $75.95 in premarket trading.

Portfolio Pulse from Anusuya Lahiri

January 02, 2024 | 1:21 pm

FIX

Comfort Systems USA has entered into an agreement to acquire Summit Industrial Construction, LLC. Summit is expected to contribute annualized revenues of $300M-$400M to Comfort Systems USA.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 1:18 pm

ZION

Zions Bancorp (NASDAQ:ZION) has received mixed analyst ratings over the past three months, with 13 analysts offering diverse perspectives. The average 12-month price target for ZION has increased by 7.52% to $39.31. Analysts from firms such as Barclays, Goldman Sachs, Truist Securities, Baird, Wells Fargo, Citigroup, Piper Sandler, JP Morgan, and Wedbush have updated their ratings and price targets, reflecting changes in market dynamics and company performance. Zions Bancorp's financial performance shows a revenue decline of -7.61% for the quarter ending September 30, 2023, a net margin of 21.83%, an ROE of 3.44%, an ROA of 0.19%, and a low debt-to-equity ratio of 0.11.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 1:00 pm

STT

State Street (NYSE:STT) has been evaluated by 5 analysts over the last three months, with recent ratings ranging from 'Somewhat Bullish' to 'Indifferent'. The average 12-month price target for STT is now $84.2, up from $80.25, with a high estimate of $102.00 and a low of $77.00. Analysts have adjusted their ratings and price targets in response to market dynamics and company performance. State Street, a financial services provider with significant assets under management and custody, faces challenges in revenue growth, net margin, ROE, and ROA, but maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

January 02, 2024 | 1:00 pm

STRM

Streamline Health Solutions, Inc. (NASDAQ:STRM) has expanded its contract with a current client, a 6 facility health system using Oracle Cerner-EHR, to include RevID's automated charge reconciliation and the eValuator Pro Fee module. The client, which has been using eValuator for pre-bill code auditing for over 3 years, also extended the overall agreement term by an additional 3 years.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 12:33 pm